CIDRAP-ASP Reports

CIDRAP-ASP publishes a variety of reports and policy briefs on topics relevant to antimicrobial resistance (AMR) and antimicrobial stewardship around the world.

Outcomes Research and AMR

Outcomes Research & AMR I: Defining the Value of Healthcare Interventions in Antimicrobial Resistance (2023)
CIDRAP-ASP's Francesca Chiara, PhD, MRes, MSc, and Natalie Vestin, MPH, define outcomes research, explore how the concept has evolved over time, and describe how outcomes research can be applied to AMR interventions. The report is the first in a series of policy briefs supported by a grant from bioMérieux.


Outcomes Research & AMR II: Bringing Value to the Care Pathway: The Rising Role of Rapid Diagnostics (2023)
CIDRAP-ASP's Francesca Chiara, PhD, MRes, MSc, and Natalie Vestin, MPH, explore the role of outcomes research in making the value case for rapid diagnostics that help to identify infectious diseases and prevent AMR. Two case studies illuminate the role of outcomes research in: 1) clarifying the cost-effectiveness of rapid diagnostics for sepsis in different health contexts and 2) evaluating the cost-effectiveness of rapid diagnostics for invasive fungal infections in people living with HIV in Guatemala. The report is the second in a series supported by a grant from bioMérieux.


Outcomes Research & AMR III: A Human-Centered Perspective on a Biosocial Problem (2023)
CIDRAP-ASP's Francesca Chiara, PhD, MRes, MSc, and Natalie Vestin, MPH, provide a socioeconomic perspective on AMR outcomes and cost-effectiveness research, advocating for greater consideration of social sciences perspectives, regional diversity and heterogeneity, and systems-based thinking in addressing the societal impacts and costs of AMR.

Other Reports

Filling the 'Discovery Void:" Policy Incentives and Antimicrobial Stewardship to Encourage Antibiotic Innovation (2023)
University of Minnesota MPH candidate Holden Baker explores current thinking and policy on incentives for antibiotic development, with special attention to the role of the US policymaker. The report was produced in fulfillment of the University of Minnesota School of Public Health Applied Practice Experience (APEx) and in collaboration with CIDRAP-ASP. CIDRAP-ASP's Natalie Vestin, MPH, served as APEx preceptor.


Antifungal Therapy Guidelines for Pediatric Acute Leukemia Patients Infected with Candida and Aspergillus Species (2023)
Ingrid Jacobson, MPH, explores antifungal guidelines for treating suspected or confirmed Candida spp. and Aspergillus spp. infections in children with acute leukemia. The report was produced in fulfillment of the University of Minnesota School of Public Health Applied Practice Experience (APEx) and in collaboration with CIDRAP-ASP. CIDRAP-ASP's Natalie Vestin, MPH, served as APEx preceptor.


A Vaccine is a Bridge: The New Era of Typhoid Prevention (2022)
CIDRAP-ASP's Natalie Vestin, MPH, describes the global burden of typhoid, the emergence of drug-resistant strains, and the role that typhoid conjugate vaccine campaigns could play in typhoid prevention and control. The report was supported by a grant from Wellcome.


The Limit of Limits: India’s Hurdles in Regulating Antimicrobial Pollution (2022)
CIDRAP-ASP's Natalie Vestin, MPH, analyzes the role of antibiotic contaminants in pharmaceutical wastewater and global discussion surrounding India's proposal to become the first country in the world to set limits on antimicrobial levels in wastewater discharged from pharmaceutical factories. The report was supported by a grant from Wellcome.

Our underwriters